50 completed, 12 terminated, 11 recruiting, 5 active not recruiting. 57 Phase 2, 23 Phase 1, 5 Early Phase 1, 2 Phase 4.
Follow HhAntag691: new trials by email Literature Review of HhAntag691 trials Research Report on HhAntag691
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer Atezolizumab, Biospecimen Collection, Computed Tomography - Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma | Phase 1 | Suspended | Dwight Owen | 24 | 2024-12-31 | 2026-09-18 |
| To Assess the Safety and Efficacy of SP-002 with Vismodegib for the Treatment of Locally Advanced Basal Cell Carcinoma SP-002, Vismodegib - Basal Cell Carcinoma | Phase 2 | Recruiting | Stamford Pharmaceuticals, Inc. | 80 | 2024-04-09 | 2024-09-20 |
| Radiotherapy by Sonic Hedgehog Pathway Inhibitors in Basal Cell Carcinoma Radiotherapy, Observation, Vismodegib - Basal Cell Carcinoma, Radiotherapy; Complications | Phase 2 | Recruiting | University Hospital, Lille | 82 | 2023-06-20 | 2025-09-30 |
| Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer Vismodegib, Atezolizumab - Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma | Phase 2 | Recruiting | Ronald Buckanovich | 48 | 2023-05-15 | 2026-06-18 |
| Adaptive Therapy of Vismodegib in Advanced Basal Cell Carcinoma Vismodegib 150 MG Oral Capsule - Advanced Basal Cell Carcinoma | Early Phase 1 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 34 | 2023-03-23 | 2026-04-01 |
| SMMART Adaptive Clinical Treatment (ACT) Trial Alectinib, Alpelisib, Anastrozole - Advanced Breast Carcinoma, Advanced Malignant Solid Neoplasm | Early Phase 1 | Withdrawn | OHSU Knight Cancer Institute | 2023-01-30 | 2024-01-23 | |
| The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs Alectinib, Cobimetinib, Vismodegib - Advanced Cancer, Solid Tumor | Phase 2 | Recruiting | Helsinki University Central Hospital | 250 | 2021-12-10 | 2024-07-15 |
| Oral Hedgehog Inhibitors in the Treatment of Basal Cell Carcinoma in the Netherlands: a Prospective Registration Study Vismodegib, Sonidegib - Basal Cell Carcinoma, Locally Advanced Basal Cell Carcinoma | Recruiting | Maastricht University Medical Center | 80 | 2021-11-01 | 2025-04-04 | |
| Improving Public Cancer Care by Implementing Precision Medicine in Norway Atezolizumab - Cancer Metastatic | Phase 2 | Recruiting | Oslo University Hospital | 3000 | 2021-04-01 | 2024-02-29 |
| ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling Alectinib, Atezolizumab, Avelumab - Cancer, Tumors | Phase 2 | Recruiting | Ulrik Lassen | 300 | 2020-08-24 | 2025-07-25 |
| Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial Abemaciclib, Abiraterone, Afatinib - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 | Terminated | OHSU Knight Cancer Institute | 2 | 2020-04-01 | 2024-03-04 |
| Nivolumab With Vismodegib in Patients With Basal Cell Nevus Syndrome Vismodegib, Nivolumab, Ipilimumab - Basal Cell Nevus Syndrome | Phase 2 | Withdrawn | Columbia University | 2019-07-01 | 2019-12-18 | |
| Relationship Between Pharmacokinetics and Safety of Vismodegib - OPTIVISMO-1 Treatment with vismodegib - Metastatic Basal Cell Carcinoma, Locally Advanced Basal Cell Carcinoma | Phase 4 | Completed | University Hospital, Bordeaux | 27 | 2018-09-03 | 2026-05-19 |
| A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site Alectinib, Vismodegib, Ipatasertib - Cancer of Unknown Primary Site | Phase 2 | Completed | Hoffmann-La Roche | 529 | 2018-07-10 | 2025-11-19 |
| NCT Neuro Master Match - N²M² (NOA-20) APG101, Alectinib, Idasanutlin - Glioblastoma, Adult | Phase 1 / Phase 2 | Completed | University Hospital Heidelberg | 228 | 2018-05-07 | 2023-09-28 |
| Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR) Olaparib, Dasatinib, Nivolumab plus Ipilimumab - Lymphoma, Non-Hodgkin, Multiple Myeloma | Phase 2 | Recruiting | Canadian Cancer Trials Group | 720 | 2018-03-23 | 2026-03-27 |
| Study of Vismodegib in Advanced Gastric Adenocarcinoma Patients With SMO Overexpression Vismodegib 150 mg - Stomach Neoplasms | Phase 2 | Completed | Samsung Medical Center | 10 | 2017-02-10 | 2021-06-08 |
| Neoadjuvant Vismodegib in Patients With Large and/or Recurrent Resectable Basal Cell Carcinoma Vismodegib - Basal Cell Carcinoma | Phase 2 | Completed | SRH Wald-Klinikum Gera GmbH | 40 | 2017-01-01 | 2022-02-11 |
| To Assess The Efficacy And Safety Of Vismodegib And Radiotherapy In Advanced Basal Cell Carcinoma Vismodegib, Radiotherapy - Carcinoma, Basal Cell | Phase 2 | Terminated | Istituto Clinico Humanitas | 14 | 2016-10-01 | 2020-01-29 |
| The Drug Rediscovery Protocol (DRUP Trial) Panitumumab, Olaparib, Dabrafenib - Cancer, Tumors | Phase 2 | Recruiting | The Netherlands Cancer Institute | 1550 | 2016-08-01 | 2024-01-24 |
Showing 20 of 85. Sign in to see all of them.
Carcinoma, Basal Cell (25) · Neoplasms (8) · Pancreatic Neoplasms (8) · Breast Neoplasms (5) · Medulloblastoma (5) · Multiple Myeloma (5) · Prostatic Neoplasms (5) · Basal Cell Nevus Syndrome (4) · Ovarian Neoplasms (4) · Skin Neoplasms (4) · Colorectal Neoplasms (3) · Hematologic Neoplasms (3) · Stomach Neoplasms (3) · Adenocarcinoma (2) · Brain Neoplasms (2)
National Cancer Institute (NCI) (18) · Genentech, Inc. (14) · Hoffmann-La Roche (10) · Mayo Clinic (2) · OHSU Knight Cancer Institute (2) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (2) · UCSF Benioff Children's Hospital Oakland (2) · University Hospital, Lille (2) · University of Arizona (2) · Abel Torres, MD (1) · Alliance for Clinical Trials in Oncology (1) · Anne Chang (1) · Canadian Cancer Trials Group (1) · Centre Leon Berard (1) · Clinica Universidad de Navarra, Universidad de Navarra (1)
United States (51) · France (10) · Germany (10) · Canada (7) · Italy (6) · Netherlands (5) · United Kingdom (5) · Australia (4) · Spain (4) · Austria (3) · Belgium (3) · Denmark (3) · Finland (3) · Mexico (3) · Norway (3)
Amar Gajjar (3) · Ervin Epstein, MD (2) · Jennifer Low, M.D. (2) · Abel Torres, MD (1) · Albert Cornelius, MD (1) · Amar Gajjar, MD (1) · Ana De Jesus-Acosta, MD (1) · Anne Lynn S Chang, MD (1) · Anne S Tsao (1) · Antoine Italiano (1) · Armando Santoro, MD (1) · Brian L Schmidt, DDS, MD, PhD (1) · Cagri Besirli, M.D., Ph.D. (1) · Carol Huff (1)
PMID 26169613, PMID 27581207, PMID 19726763, PMID 20818327, PMID 22670903, PMID 22670904, PMID 23342272, PMID 24170610, PMID 24623282, PMID 24929884, PMID 25278454, PMID 25981813, PMID 26527777, PMID 26586415, PMID 27054919, PMID 27154174, PMID 27826729, PMID 27838224, PMID 28188086, PMID 28250200, PMID 28325399, PMID 28511673, PMID 29073584, PMID 29320312, PMID 29777299, PMID 30249277, PMID 30857956, PMID 31857726, PMID 32026407, PMID 32374193, PMID 32463741, PMID 33048619, PMID 33823018, PMID 33988881, PMID 33997740, PMID 34339623, PMID 34876409, PMID 35086719, PMID 35133871, PMID 35138919, PMID 35281856, PMID 35568909, PMID 35598186, PMID 35649212, PMID 36288512, PMID 36351402, PMID 36455049, PMID 36814246, PMID 36870947, PMID 36951168
2015 (3), U01CA081457 (3), U10CA180820 (3), N01CM00038 (2), N01CM00071 (2), P30CA014599 (2), U01CA070095 (2), 2014 (1), 2017 (1), N01CM00039 (1), N01CM00070 (1), N01CM62201 (1), N01CM62202 (1), N01CM62204 (1), N01CM62206 (1)